Phase 3 Stroke Trial, Recruiting NCT05105633 Sponsor: University of Melbourne Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT05105633
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are showing symptoms of a stroke affecting the back part of the brain (posterior circulation stroke), caused by a partial or complete blockage of a major artery at the base of the brain called the basilar artery.
  • Symptoms must have started — or the person must have been last seen well — within the past 24 hours.
  • The basilar artery blockage must be confirmed by a CT scan or MRI scan of the blood vessels.
  • People aged 18 years or older.
  • People who, before this stroke, were either fully independent or needed only minor help at home and could manage on their own for at least one week (a disability score of 3 or less on a standard scale).
  • Consent requirements under local laws must have been met.

Who may not be able to join:

  • People whose brain scan shows bleeding in the brain or another condition such as a brain tumour.
  • People whose brain scan shows a low score on a specific rating system (called pc-ASPECTS) that suggests a large area of the brain has already been seriously damaged (score below 7).
  • People showing signs of significant swelling in the cerebellum (back of the brain) or a dangerous build-up of fluid on the brain (acute hydrocephalus).
  • People whose CT scan shows a large area of the brain has already died, suggesting the stroke happened some time ago.
  • People with extensive damage to both sides of the brainstem.
  • People where the treating doctor suspects the blockage is due to longstanding narrowing of the arteries or a tear in an artery wall, which may need a different type of procedure rather than clot-dissolving medication.
  • People who, before this stroke, already had moderate to severe disability (a score of 4 or more on a standard disability scale).
  • People who have other standard medical reasons why clot-dissolving medication given through a drip would not be safe (confirm with trial site).
  • People who cannot have contrast dye used during scans.
  • People who are visibly pregnant.
  • People who are currently taking part in another research study involving a drug treatment.
  • People with a known terminal illness where survival beyond one year would not be expected.
  • People for whom a decision has already been made to withdraw active treatment or move to comfort care only.
  • People where the treating doctor judges that joining the study could pose a risk to their safety or affect their ability to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bruce Campbell, University of Melbourne

Phone: +6193424424

Australian sites

Bankstown-Lidcombe Hospital, Bankstown, New South Wales
John Hunter Hospital, Newcastle, New South Wales
Liverpool Hospital, Sydney, New South Wales
Gold Coast Hospital, Gold Coast, Queensland
Princess Alexandra Hospital, Woolloongabba, Queensland
Royal Adelaide Hospital, Adelaide, South Australia
Alfred Health, Melbourne, Victoria
Austin Hospital, Melbourne, Victoria
Box Hill Hospital, Melbourne, Victoria
Monash Health, Melbourne, Victoria
Royal Melbourne Hospital, Melbourne, Victoria
+619342 4424
Western Health, Melbourne, Victoria
Fiona Stanley Hospital, Murdoch, Western Australia
Grampians Health, Ballarat,
+61(03) 53305104
Northern Hospital, Melbourne,
+61(03) 8405 8000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Melbourne
Registry
ClinicalTrials.gov
Start date
29 November 2021
Est. completion
1 May 2028

Where this trial is recruiting

🇦🇺 Australia 🇧🇷 Brazil 🇫🇷 France

15 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Modified Rankin Scale (mRS) 0-1 or return to baseline mRS at 90 days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov